966
Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia.
 blood glucose-lowering effect and increase the risk of hypoglycemia: Effect; Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide: Treatment; clarithromycin: Treatment.Drug; potent inhibitors of CYP3A4: Treatment.Drug; repaglinide: Treatment.Drug; clarithromycin: Combination.Drug; repaglinide: Combination.Drug; potent inhibitors of CYP3A4: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 blood glucose-lowering effect and increase the risk of hypoglycemia: Effect; Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide: Treatment; clarithromycin: Treatment.Drug; potent inhibitors of CYP3A4: Treatment.Drug; repaglinide: Treatment.Drug; clarithromycin: Combination.Drug; repaglinide: Combination.Drug; potent inhibitors of CYP3A4: Combination.Drug